Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Provide Cancer Test for Patients Taking Amgen Drug

NEW YORK (GenomeWeb News) – Amgen said today that it has partnered with Lab21 to launch a new genetic test for patients in the UK taking Amgen’s Vectibix (panitumumab) for advanced bowel cancer.
 
The screening test was developed by British molecular diagnostics firm DxS, which sells a range of cancer mutation diagnostic products.
 
Vectibix was launched in the UK earlier this year for patients with metastatic bowel cancer for whom standard chemotherapy has failed and who have a specific gene mutation, according to a statement from Amgen Limited UK. The firm said that during clinical studies the drug doubled median progression-free survival in patients with non-mutated, or wild type, Kirsten Rat Sarcoma 2 viral oncogene homologue compared with patients who received “best supportive care alone.”
 
According to Amgen, patients with metastatic bowel cancer will be tested for the wild type KRAS gene before being prescribed the drug.
 
It said that Vectibix approval marked the first time that the European Commission licensed a bowel cancer product with the stipulation that a predictive test should be carried out.
 
“This is a big step forward towards individualized care in bowel cancer,” said Charles Brigden, medical director of Amgen Limited, in a statement.
 
Terms of the agreement were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.